Market Opportunity

Urinary Tract Infections

$8 billion

~ 1 in 2 Women &

Most Common

Hospital Acquired Infection [5]

Bladder Overactivity

$4 billion

> 10% of Adults

Increases with Age [2]

Bladder Cancer

$2 billion

> 81K New Cases in US 2018 [3]

Pain & Inflammation

$4 billion

~ 3 to 8 million Women in US [4]

UroPharma is uniquely positioned to bring a number of direct to bladder treatments to people with bladder diseases and disorders, notably people with neurological conditions, e.g. urinary tract infections (UTI), bladder cancer, multiple sclerosis (MS), spinal cord injuries (SCI), overactive bladder (OAB) and pain & inflammation.

UroPharma can roll out drug-delivery combinations into each of the 4 target markets shown in the graphic. Due to the aging of populations, these target markets are expected to increase substantially.

Contact Us

Tel: +44 (0) 1603 626 960

Email: info@uropharma.com

Social Media

  • LinkedIn Social Icon

Linkedin.com/company/uropharma

  • Twitter

Twitter.com/UroPharma

  • Facebook

Facebook.com/bladdercontrol

©2017-2020 UroPharma, Inc. All Rights Reserved